Osteoporosis

Spine

Volumn 26, Issue 8, 2001, Pages 930-932

  Truumees, E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ESTROGEN; RALOXIFENE; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BONE DENSITY; CONFERENCE PAPER; ESTROGEN THERAPY; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; VERTEBRA FRACTURE;

HUMANS; OSTEOPOROSIS; SPINAL FRACTURES;

EID: 0035870992     PISSN: 03622436     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007632-200104150-00016     Document Type: Conference Paper

References (23)

1. Effects of gender and age differences on the distribution of bone content in the third lumbar vertebra
2. Hip fractures in Finland between 1070 and 1997 and predictions for the future
3. Epidemiology of vertebral fractures in women
4. Epidemiology of Osteoporosis
5. New guidelines for the prevention and treatment of osteoporosis
6. Osteoporosis in men
7. The management of osteoporosis-related fractures: A survey of orthopaedic surgeons' practice
8. The challenges of peripheral bone density testing: Which patients need additional central density skeletal measurements?
9. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women
10. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment
11. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group
12. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene
13. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group
14. Risedronate reverses bone loss in postmenopausal women with low bone mass: Results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group
15. Effect of Alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures
16. A review of clinical trials of therapies for osteoporosis using fracture as an end point
17. HMG-CoA Reductase Inhibitors and the Risk Fractures
18. Percutaneous vertebroplasty with polymethylmethacrylate. Technique, indications, and results
19. Vertebroplasty: Clinical experience and follow-up results
20. Percutaneous vertebroplasty guided by a combination of CT and fluoroscopy
21. Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral body compression fractures: Technical aspects
22. Percutaneous Vertebroplasty for Pain Relief and Spinal Stabilization